



FDA ADVISORY
No. **2020-1126**

15 JUN 2020

TO: GENERAL CONSUMING PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of Cosmetic Product BEAUCHE CLARIFYING SOLUTION Containing Banned Ingredient/s

The Food and Drug Administration (FDA) warns the public from purchasing and using the adulterated cosmetic product **BEAUCHE CLARIFYING SOLUTION** which tested positive for the presence of **HYDROQUINONE** and **TRETINOIN**. Such ingredients are not allowed to be part of a cosmetic product as per Annex II Part 1 of the ASEAN Cosmetic Directive. As per Administrative Order No. 13 s. 1999, products containing Hydroquinone and/or Tretinoin (Retinoic Acid) are classified as home remedy, over-the-counter, or prescription drug. The table below indicates the particulars of the adulterated cosmetic product/s:

PRODUCT DETAILS	PRODUCT IMAGE/S
<p>Name of Manufacturer/ Local Company Responsible for Placing the Product in the Market: Beauche International by Conchita, Inc.</p> <p>Address: Blk 6 Lot 9-11, Dasmariñas Technopark, Brgy. Paliparan I, Dasmariñas City, Cavite, Philippines 4114</p> <p>Country of Manufacture: Philippines</p> <p>Lot/Batch Number: 7209193025 Mfg. Date: 25 JUL 2019 Exp. Date: 25 JUL 2021</p>	



The aforementioned adulterated product is found to be non-compliant with the existing standards, and, thus pose potential hazards to the consuming public. The use of adulterated cosmetic products may result to adverse reactions, including but not limited to, skin irritation, itchiness, anaphylactic shock and organ failure.


In light of the foregoing, the public is advised not to purchase the aforementioned adulterated cosmetic product. Moreover, the public is advised to always check if a cosmetic product is notified with the FDA through its website (www.fda.gov.ph). It has a *Search* feature which may be used by typing in the name of the product before deciding on purchasing and/or using the said product.

All concerned establishments are warned not to distribute adulterated cosmetic products.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of their jurisdiction.

To report any sale, distribution, complaint and/or adverse event on the use of the violative cosmetic product, the online reporting facility, eReport can be accessed at ereport@fda.gov.ph, or call us at the Center for Cosmetics Regulation and Research (CCRR) hotline **(02) 8857-1900 loc. 8113 or 8107**.

Dissemination of this advisory to all concerned is hereby requested.


ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN 20200605112306